Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Lymphoma 13Neuroblastoma 10Leukemia 9Central Nervous System Neoplasms 9Sarcoma 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Brain Neoplasms 8Hodgkin Disease 5Burkitt Lymphoma 5Neuroectodermal Tumors, Primitive, Peripheral 4Lymphoma, Large B-Cell, Diffuse 4Dendritic Cell Sarcoma, Interdigitating 4Medulloblastoma 3Leukemia, Biphenotypic, Acute 3Astrocytoma 3Wilms Tumor 2Testicular Neoplasms 2Teratoma 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Recurrence 2Osteosarcoma 2Myelodysplastic Syndromes 2Multiple Myeloma 2Malignant mesenchymal tumor 2Leukemia, Myeloid, Acute 2Leukemia, Monocytic, Acute 2Kidney Neoplasms 2Cardiotoxicity 2Carcinoma, Renal Cell 2

Interventions

pegfilgrastim 1Taxes 1Platinum 1Paclitaxel 1Granulocyte Colony-Stimulating Factor 1Fulvestrant 1Filgrastim 1Doxorubicin 1Cisplatin 1Carboplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Recurrent Uterine Corpus Carcinoma × Granulocyte Colony-Stimulating Factor × Clear all
NCT00063999 2021-10-19

Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

GOG Foundation

Phase 3 Completed
1,381 enrolled 12 charts
Gynecologic

Recurrent Uterine Corpus Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡